Nitsche Christoph
Research School of Chemistry, Australian National University, Canberra, ACT, 2601, Australia.
Biophys Rev. 2019 Apr;11(2):157-165. doi: 10.1007/s12551-019-00508-3. Epub 2019 Feb 26.
Proteases from flaviviruses have gained substantial interest as potential drug targets to combat infectious diseases caused by dengue, West Nile, Zika and related viruses. Despite nearly two decades of drug discovery campaigns, promising lead compounds for clinical trials have not yet been identified. The main challenges for successful lead compound development are associated with limited drug-likeness of inhibitors and structural ambiguity of the protease target. This brief review focuses on the available information on the structure of flavivirus proteases and their interactions with inhibitors and attempts to point the way forward for successful identification of future lead compounds.
黄病毒蛋白酶作为对抗登革热、西尼罗河病毒、寨卡病毒及相关病毒引起的传染病的潜在药物靶点,已引起了广泛关注。尽管经过了近二十年的药物研发,但尚未确定有前景的用于临床试验的先导化合物。成功开发先导化合物的主要挑战与抑制剂的类药性质有限以及蛋白酶靶点的结构不明确有关。本简要综述聚焦于黄病毒蛋白酶结构及其与抑制剂相互作用的现有信息,并试图为成功鉴定未来的先导化合物指明方向。